Hyperprogressive Disease in Patients With Urothelial Carcinoma or Renal Cell Carcinoma Treated With PD-1/PD-L1 Inhibitors
Author:
Publisher
Elsevier BV
Subject
Urology,Oncology
Reference30 articles.
1. Cancer statistics, 2019;Siegel;CA Cancer J Clin,2019
2. Nivolumab versus everolimus in advanced renal-cell carcinoma;Motzer;N Engl J Med,2015
3. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma;Motzer;N Engl J Med,2018
4. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma;Rini;N Engl J Med,2019
5. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma;Motzer;N Engl J Med,2019
Cited by 34 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Hyperprogressive disease in patients with advanced cancer treated with immune checkpoint inhibitors;Clinical and Translational Oncology;2024-09-03
2. Regulatory T cells as crucial trigger and potential target for hyperprogressive disease subsequent to PD-1/PD-L1 blockade for cancer treatment;International Immunopharmacology;2024-05
3. Tumor growth rate to assess therapy response to immune-based combinations for metastatic renal cell carcinoma;Expert Review of Precision Medicine and Drug Development;2024-03-18
4. Incidence of immunotherapy‐related hyperprogressive disease (HPD) across HPD definitions and cancer types in observational studies: A systematic review and meta‐analysis;Cancer Medicine;2024-02
5. Navigating the ICI Combination Treatment Journey: Patterns of Response and Progression to First-Line ICI-Based Combination Treatment in Metastatic Renal Cell Carcinoma;Journal of Clinical Medicine;2024-01-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3